Pfizer Opens Biotech Plant In Sweden

NEW YORK (AP) -- Drugmaker Pfizer Inc. said Tuesday it opened a new biotech facility in Sweden, which will be used to make products including a branded version of human growth hormone.

Pfizer said it invested 150 million Euros ($214.8 million) in the plant in Strangnas. The facility is 6,000 square meters, or about 64,600 square feet. Products made at the plant will include Pfizer's human growth hormone, or Genotropin, along with the drug Somavert for acromegaly, and drugs based on E. coli and yeast.

In morning trading, Pfizer shares rose 9 cents to $16.82.

More in Operations